Jeong Hwan Yook

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jeong Hwan

Contact Jeong Hwan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.

Claim your profile

Articles

PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer | Journal of Clinical Oncology

Jun 16, 2021 |

By Yoon-Koo Kang, Young-Kyu Park, Jong Seok Lee, Jeong Hwan Yook

| ascopubs.org

Adjuvant treatment for locally advanced gastric cancer (LAGC) has evolved over two decades. After much debate, the efficacy of this approach was established in four pivotal trials1-4; however, standard adjuvant treatment differs regionally.

Open in Who Shared

See all 1 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.

Claim your profile

Get in touch with Jeong Hwan

Contact Jeong Hwan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Overview

Use Cases

Capabilities

Industries

Library

Commmunity

Customers

Jeong Hwan Yook

Get in touch with Jeong Hwan

Actions

Is this you?

Articles

PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer | Journal of Clinical Oncology

Actions

Is this you?

Get in touch with Jeong Hwan